Johnson & Johnson has decided not to exercise its option to license Genmab's HexaBody-CD38 antibody therapeutic, despite promising clinical efficacy data in multiple myeloma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.